【摘要】：目的評價(jià)阿德福韋對比恩替卡韋治療慢性乙型病毒性肝炎(乙肝)的臨床療效及安全性。方法 86例慢性乙肝患者隨機(jī)分為阿德福韋組(41例)和恩替卡韋組(45例),分別口服阿德福韋0.5 mg·d-1和恩替卡韋10 mg·d-1,療程均為12個月。比較2組患者治療前后乙肝病毒(HBV)DNA載量、病毒轉(zhuǎn)陰率及藥品不良反應(yīng)。結(jié)果治療12個月后,阿德福韋組與恩替卡韋組患者HBV DNA病毒載量[(4.21±0.71)vs(4.01±0.68)log10copies·m L-1]較治療前均明顯降低,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。2組HBV DNA轉(zhuǎn)陰率及谷丙轉(zhuǎn)氨酶(ALT)正常率差異無統(tǒng)計(jì)學(xué)意義(P0.05)。2組患者不良反應(yīng)發(fā)生率差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論阿德福韋與恩替卡韋治療慢性乙肝均有較好的臨床療效,且不良反應(yīng)輕微。
[Abstract]:Objective to evaluate the efficacy and safety of adefovir contrast entecavir in the treatment of chronic viral hepatitis B. Methods 86 patients with chronic hepatitis B were randomly divided into adefovir group (n = 41) and entecavir group (n = 45). Hepatitis B virus (HBV) DNA load, virus negative rate and adverse drug reaction were compared before and after treatment. Results after 12 months of treatment, the viral load of HBV DNA in adefovir group and entecavir group [(4.21 鹵0.71) vs (鹵0.68) log10copies mL -1] was significantly lower than that before treatment. There was no significant difference in the negative rate of HBV DNA and the normal rate of alanine aminotransferase (ALT) in group 2 (P0.05). There was no significant difference in the incidence of adverse reactions in group 2 (P0.05). Conclusion both adefovir and entecavir have good clinical efficacy in the treatment of chronic hepatitis B, and the adverse reactions are mild.
【作者單位】： 遂昌縣人民醫(yī)院藥劑科;麗水市人民醫(yī)院感染科;
【基金】：浙江麗水市科技基金資助項(xiàng)目(2012JYBZ15)
【分類號】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 唐茂華;陳積;饒麗萍;;恩替卡韋、阿德福韋、拉米夫定治療慢性乙型肝炎的療效比較[J];廣東醫(yī)學(xué)院學(xué)報(bào);2012年02期

2 柴艷云;李建國;張新龍;;阿德福韋酯與恩替卡韋治療HBeAg陽性慢性乙型肝炎患者臨床療效觀察[J];實(shí)用肝臟病雜志;2014年03期

3 戰(zhàn)寒秋;孫娜;劉慧;王麗君;楊玉英;;恩替卡韋單藥與拉米夫定聯(lián)合阿德福韋治療慢性乙型肝炎的回顧性分析[J];臨床藥物治療雜志;2013年06期

【共引文獻(xiàn)】

相關(guān)期刊論文 前6條

1 倪傳斌;龍波;;拉米夫定及恩替卡韋預(yù)防和治療非霍奇金淋巴瘤相關(guān)性HBV再激活的療效對比[J];臨床肝膽病雜志;2014年04期

2 譚海宏;;淺談恩替卡韋新藥的藥理作用及其抗乙肝病毒的效果[J];當(dāng)代醫(yī)藥論叢;2015年01期

3 季e，

本文編號：2144490